BioSpace News Archive

Edison Oncology Holding Corp., a company established to develop and commercialize new therapies targeting the fight against cancer, today announced that Dennis Brown , Ph.D., chairman and Jeffrey Bacha , chief executive officer, will participate in the SVB Leerink 10 th Annual Global Healthcare Conference

The American Society for Preventive Cardiology is excited to announce that Erin Michos, MD, MHS, FASPC has accepted the position of Co-Editor-in-Chief of the American Journal of Preventive Cardiology.

Combination of the Wyss’ electrochemical sensing technology with GBS’s transistor technology could enable fast, multiplexed, low-cost COVID-19 biomarker analysis in point-of-care applications.

TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence, announced that COVID-19 vaccination data is now available within the TriNetX platform and real-world data set for clinical and observational research.

Air Techniques, Inc., a leading innovator and manufacturer of dental equipment, will be sponsoring the course “A Practical Approach to Aerosol Mitigation,” presented by Dr. Martin Koch for the first time at the Chicago Midwinter Meeting.

OBIO® is proud to announce the success of the 2021 OBIO Investment Summit, February 9-10, 2021, which showcased the strength and opportunity in Canada’s health science industry.

Study to Bolster Clinical Performance Evidence of TAEUS® Ultrasound Device in NAFLD Patients as Commercialization Begins

Partnership aims to accelerate access to breakthrough therapies in order to combat difficult-to-treat and often drug-resistant fungal infections in Greater China SCYNEXIS will receive a $10 million upfront payment and will also be eligible to receive development and commercial milestones, plus low double-digit royalties on net product sales

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl,

Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced that it approved equity awards for 7 new employees with a grant date of February 16, 2021 pursuant to Myovant’s 2020 Inducement Plan.